Citi sees Daiichi supply review as immaterial for AstraZeneca

On: April 28, 2026, 4:49 pm EDT

URL has been copied successfully!

Share this story:

Previous Post:Bankruptcy court, citing Saks Global’s merchandising woes, approves $500M in exit financing

Next Post:Pension-fund rebalancing and other red flags that suggest a stock-market pullback is nearing, according to Goldman Sachs